TerraBioGen Technologies Inc.

TerraBioGen Technologies Inc.

July 14, 2015 10:00 ET

TerraBioGen Closes Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 14, 2015) -

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, announces that it has closed a private placement.

The private placement is for 42,000 units at $10.00 per unit for proceeds of $420,000. Each unit consists of one common share and one warrant exercisable at $12.00 per share for 5 years.

These funds will be used to enhance the Company's commercialization efforts through further product development, field trials, collaboration development, and securing intellectual property rights.

About TerraBioGen

TerraBioGen Technologies Inc. has developed technologies for the production of innovative, high value, environmentally progressive agricultural and horticultural bio-products that improve crop health and yields, and suppress crop disease. The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Further, the Company is taking steps to secure intellectual property rights to these active ingredients and to formulate them in order to fully commercialize their potential.

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

Contact Information

  • TerraBioGen Technologies Inc.
    Blair Heffelfinger
    President & CEO
    (604) 444-1023 ext 316
    (604) 444-1043 (FAX)
    bheffelfinger@terrabiogen.com

    TerraBioGen Technologies Inc.
    Bob Nowell
    CFO & Corporate Secretary
    (604) 444-1023 ext 306
    (604) 444-1043 (FAX)
    bnowell@terrabiogen.com